The Enzyme that Destroys Inhibition
If receptors are the locks and GABA molecules are the keys, then GABA Transaminase (GABA-T) is the smelter that melts the keys down. GABA-T (encoded by the ABAT gene) is a mitochondrial enzyme responsible for the catabolism of GABA into succinic semialdehyde. This reaction, which requires the cofactor Pyridoxal 5'-Phosphate (PLP), effectively removes GABA from the cellular pool, eventually shunting its carbon skeleton into the Krebs cycle for energy production.
Lessons from Vigabatrin (Sabril)
The clinical efficacy of inhibiting GABA-T is well established. Vigabatrin (gamma-vinyl-GABA) is a "suicide inhibitor" that irreversibly binds to the PLP cofactor within the enzyme's active site (Lys-329), chemically crippling it. In patients with tuberous sclerosis (often comorbid with ASD), vigabatrin can significantly reduce seizures and improve some behavioral symptoms. However, its use is limited by a serious side effect: visual field constriction due to retinal toxicity. This highlights the need for more targeted, reversible, or "smart" metabolic interventions.
Engineering Allosteric Regulation
Instead of destroying the enzyme like a sledgehammer, can we install a dimmer switch? Directed evolution allows us to introduce allosteric regulatory sites into the GABA-T structure. We are engineering "feedback-sensitive" GABA-T variants that are inhibited by specific endogenous signaling molecules whose levels are altered in ASD (e.g., specific neuropeptides or oxidative stress markers). In this scenario, the enzyme would function normally under baseline conditions, but would shut itself down when the "stress" of the circuit increases, preserving GABA exactly when the brain needs it most to quell a hyperexcitable storm.
Computational Docking and Rational Design
To guide our evolutionary searches, we utilize massive computational power. Molecular dynamics (MD) simulations help us visualize the flexible "breathing" motions of the enzyme. By virtually docking thousands of potential inhibitor molecules into the crystal structure of GABA-T, we can design novel pharmacophores that fit the active site with higher specificity than vigabatrin, potentially avoiding the off-target effects in the retina. This "rational design first, evolution second" approach accelerates the discovery of metabolic modulators that are both potent and safe.
Excerpt from: Harnessing Directed Evolution Techniques to Target GABA Receptors, Transporters, and GABA Transaminase in ASD by Peter De Ceuster
© All rights reserved. Do not distribute.